Company: HROW
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001641172-25-000925
Chunk: 60

Company: HARROW, INC.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1
Chunk 60
---
, including by our competitors,
or that the rights granted thereunder will provide competitive advantages to us. In certain instances, we have acquired products that
are patented and have been subject to prior litigation challenging the validity of certain patents related to those products. In some
situations, the litigation resulted in settlement agreements that have allowed generic manufacturers to license the patent rights related
to certain products and allowing the generic manufacturer to enter the market prior to patent expiration associated with the branded
product.

We also rely on unpatented trade
secrets and know-how and continuing technological innovation in order to develop our products, formulations, which we seek to protect,
in part, by confidentiality agreements with our employees, consultants, collaborators and others, including certain service providers.
We also have invention or patent assignment agreements with our current employees and certain consultants. Nonetheless, our employees
and consultants may breach these agreements, and we may not have adequate remedies for the breach. Our trade secrets may otherwise become
known or be independently discovered by competitors or could be developed by a person not bound by an invention assignment agreement
with us, in which case we may have no rights to use the applicable invention.

We may face additional competition outside
of the U.S. as a result of a lack of patent coverage in some territories and differences in patent prosecution and enforcement laws in
foreign counties. 

Filing, prosecuting, defending
and enforcing patents on our proprietary formulations throughout the world is extremely expensive. We do not currently have patent protection
outside of the U.S. that covers any of our proprietary formulations or other assets that we are currently pursuing. Competitors may use
our technologies to develop their own products in jurisdictions where we have not obtained patent protection.

Even if the international patent
applications we have filed or may in the future file are issued or approved, it is likely that the scope of protection provided by such
patents would be different from, and possibly less than, the scope provided by corresponding U.S. patents. As a result, patent rights
we are able to obtain may not be sufficient to prevent generic competition. Further, the extent of our international market opportunity
may be dependent upon the enforcement of patent rights in various other countries. A number of countries in which we could file patent
applications have a history of weak enforcement and/or compulsory licensing of intellectual property rights. Moreover, the legal systems
of certain countries, particularly certain developing countries, do not favor the aggressive enforcement of patents and other intellectual
property protection, particularly those relating to biotechnology and